Craig T Jordan

List of Publications by Year in Descending Order

243 papers	15,369 citations	57 h-index	122 g-index
256 ext. papers	17,853 ext. citations	7.1 avg, IF	6.51 L-index

#	Paper	IF	Citations
243	309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations. *Journal of Clinical and Translational Science*, **2022**, 6, 54-54	0.4	
242	MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. *Journal of Leukocyte Biology*, **2021**, 110, 197-205	6.5	0
241	Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies. *Blood*, **2021**, 138, 2612-2612	2.2	
240	Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia. *Blood*, **2021**, 138, 630-630	2.2	
239	Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. *Blood*, **2021**, 138, 3957-3957	2.2	0
238	Unique Metabolic Vulnerabilities of Myelodysplastic Syndrome Stem Cells. *Blood*, **2021**, 138, 1511-1511	2.2	0
237	Venetoclax and Azacitidine Compared to Induction Chemotherapy for Newly Diagnosed Patients with Acute Myeloid Leukemia. *Blood Advances*, **2021**,	7.8	12
236	Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. *Bone Marrow Transplantation*, **2021**,	4.4	6
235	The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia. *Leukemia and Lymphoma*, **2021**, 62, 1466-1473	1.9	4
234	Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors. *Cell Stem Cell*, **2021**, 28, 378-393	18	14
233	Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting. *STAR Protocols*, **2021**, 2, 100248	1.4	3
232	PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress. *Journal of Experimental Medicine*, **2021**, 218,	16.6	16
231	Comprehensive Structure-Activity Profiling of Micheliolide and its Targeted Proteome in Leukemia Cells via Probe-Guided Late-Stage C-H Functionalization. *ACS Central Science*, **2021**, 7, 841-857	16.8	5
230	The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. *Cancer Discovery*, **2021**, 11, 500-519	24.4	7
229	Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. *Clinical Cancer Research*, **2021**, 27, 819-830	12.9	2
228	The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation. *Blood*, **2021**,	2.2	4
227	Antitumor properties of novel sesquiterpene lactone analogs as NFB inhibitors that bind to the IKKubiquitin-like domain (ULD). *European Journal of Medicinal Chemistry*, **2021**, 224, 113675	6.8	2

226	Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. *Cancer Discovery*, **2020**, 10, 536-551	24.4	93
225	ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. *JCI Insight*, **2020**, 5,	9.9	1
224	Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features. *Blood*, **2020**, 136, 9-9	2.2	3
223	Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy. *Blood*, **2020**, 136, 24-24	2.2	5
222	Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse. *Blood*, **2020**, 136, 11-12	2.2	6
221	Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. *Cell Stem Cell*, **2020**, 27, 748-764.e4	18	43
220	Delivery of a model lipophilic membrane cargo to bone marrow via cell-derived microparticles. *Journal of Controlled Release*, **2020**, 326, 324-334	11.7	1
219	Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. *Nature Cancer*, **2020**, 1, 1176-1187	15.4	26
218	Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. *Haematologica*, **2020**, 105, 585-597	6.6	15
217	Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors. *European Journal of Medicinal Chemistry*, **2020**, 197, 112316	6.8	6
216	Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. *Blood Advances*, **2020**, 4, 1628-1639	7.8	5
215	CD123 CAR T cells for the treatment of myelodysplastic syndrome. *Experimental Hematology*, **2019**, 74, 52-63.e3	3.1	13
214	Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. *Blood*, **2019**, 134, 389-394	2.2	62
213	Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. *Leukemia Research*, **2019**, 81, 43-49	2.7	4
212	Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. *Haematologica*, **2019**, 104, e388-e392	6.6	19
211	The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. *Cell Reports*, **2019**, 27, 238-254.e6	10.6	37
210	Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. *Clinical Cancer Research*, **2019**, 25, 4079-4090	12.9	61
209	Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?. *Current Opinion in Hematology*, **2019**, 26, 71-76	3.3	8

208	Can we selectively target AML stem cells?. *Best Practice and Research in Clinical Haematology*, **2019**, 32, 101100	4.2	8
207	Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy. *Blood*, **2019**, 134, 2638-2638	2.2	1
206	Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine. *Blood*, **2019**, 134, 1272-1272	2.2	4
205	Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy. *Blood*, **2019**, 134, 185-185	2.2	1
204	PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71. *Blood*, **2019**, 134, 3935-3935	2.2	
203	STAT3 Plays a Critical Role in Mitochondrial Function and Survival of Primary AML Cells. *Blood*, **2019**, 134, 1275-1275	2.2	
202	Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples. *Blood*, **2019**, 134, 4404-4404	2.2	
201	PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation. *Blood*, **2019**, 134, 822-822	2.2	
200	Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. *Blood Advances*, **2019**, 3, 2911-2919	7.8	60
199	CD46 Antibody Drug Conjugate Impedes Myeloma Engraftment in Patient-Derived Xenografts. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e151	2	2
198	MMB triazole analogs are potent NF-Ƀ inhibitors and anti-cancer agents against both hematological and solid tumor cells. *European Journal of Medicinal Chemistry*, **2018**, 157, 562-581	6.8	18
197	AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. *Cell Stem Cell*, **2018**, 23, 86-100.e6	18	116
196	Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant. *Blood*, **2018**, 132, 2138-2138	2.2	4
195	A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients. *Blood*, **2018**, 132, 3203-3203	2.2	1
194	PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia. *Blood*, **2018**, 132, 909-909	2.2	10
193	Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality. *Blood*, **2018**, 132, 2573-2573	2.2	0
192	Cysteine and Cystine Depletion Targets Leukemia Stem Cells. *Blood*, **2018**, 132, 431-431	2.2	
191	Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism. *Blood*, **2018**, 132, 429-429	2.2	

190	Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1. *Blood*, **2018**, 132, 432-432	2.2	1
189	MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. *JCI Insight*, **2018**, 3,	9.9	31
188	Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. *Cancer Cell*, **2018**, 34, 724-740.e4	24.3	204
187	Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. *Nature Medicine*, **2018**, 24, 1859-1866	50.5	293
186	Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. *Cancer Cell*, **2018**, 34, 659-673.e6	24.3	55
185	Functional genomic landscape of acute myeloid leukaemia. *Nature*, **2018**, 562, 526-531	50.4	391
184	Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. *Nature Communications*, **2018**, 9, 3694	17.4	41
183	Therapeutic targeting of acute myeloid leukemia stem cells. *Blood*, **2017**, 129, 1627-1635	2.2	152
182	Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. *European Journal of Medicinal Chemistry*, **2017**, 136, 393-405	6.8	14
181	Succinamide derivatives of melampomagnolide B and their anti-cancer activities. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 3694-3705	3.4	13
180	Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. *Haematologica*, **2017**, 102, 1054-1065	6.6	10
179	Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 1235-1241	3.4	7
178	A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. *Molecular Cancer Therapeutics*, **2017**, 16, 2058-2068	6.1	44
177	Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. *Leukemia and Lymphoma*, **2016**, 57, 927-34	1.9	11
176	Acute myeloid leukaemia. *Nature Reviews Disease Primers*, **2016**, 2, 16010	51.1	159
175	Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 3876-3886	3.4	24
174	SomVarIUS: somatic variant identification from unpaired tissue samples. *Bioinformatics*, **2016**, 32, 808-13	7.2	29
173	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. *JCI Insight*, **2016**, 1, e85630	9.9	36

172	MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. *Journal of Clinical Investigation*, **2016**, 126, 1438-50	15.9	26
171	Mitochondrial Fission 1 Regulates GSK3 and AMPK Signaling to Sustain Leukemia Stem Cell Function in Acute Myelogenous Leukemia. *Blood*, **2016**, 128, 1703-1703	2.2	1
170	ETV6 Regulates Pax5 Expression in Early B Cell Development. *Blood*, **2016**, 128, 2655-2655	2.2	1
169	The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis. *Blood*, **2016**, 128, 1079-1079	2.2	
168	Distinct Metabolic Properties of MDS Stem Cells Provide Novel Opportunities for Therapeutic Intervention. *Blood*, **2016**, 128, 4316-4316	2.2	
167	Development of Anti-IL-1R3 Monoclonal Antibodies for Treating Cancer and IL-1 Family-Mediated Inflammation. *Blood*, **2016**, 128, 5224-5224	2.2	
166	Adipose Tissue-Derived IGFBP1 Facilitates Progression of Leukemia. *Blood*, **2016**, 128, 3058-3058	2.2	
165	Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes. *Blood*, **2016**, 128, 3054-3054	2.2	
164	MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia. *Blood*, **2016**, 128, 4044-4044	2.2	0
163	Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. *Cell Stem Cell*, **2016**, 19, 23-37	18	267
162	Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 5855-5860	3.4	6
161	Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. *Blood*, **2016**, 128, 1671-8	2.2	127
160	ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E6669-E6678	11.5	52
159	Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. *Journal of Biological Chemistry*, **2016**, 291, 21984-22000	5.4	24
158	Micelle Delivery of Parthenolide to Acute Myeloid Leukemia Cells. *Cellular and Molecular Bioengineering*, **2015**, 8, 455-470	3.9	22
157	Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells. *Journal of Medicinal Chemistry*, **2015**, 58, 8896-906	8.3	18
156	A test of homogeneity for age-dependent branching processes with immigration. *Electronic Journal of Statistics*, **2015**, 9, 898-925	1.2	4
155	Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. *Oncotarget*, **2015**, 6, 14796-813	3.3	34

154	Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. *Cell Research*, **2015**, 25, 707-25	24.7	225
153	Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. *Clinical Cancer Research*, **2015**, 21, 1360-72	12.9	42
152	A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression. *Blood*, **2015**, 126, 4266-4266	2.2	1
151	Cellular Iron Status Is Associated with Better Survival and Increased Chemotherapy Sensitivity in AML. *Blood*, **2015**, 126, 4975-4975	2.2	2
150	Adipose Tissue Functions As a Reservoir for Leukemia Stem Cells and Confers Chemo-Resistance. *Blood*, **2015**, 126, 845-845	2.2	1
149	Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. *Oncotarget*, **2015**, 6, 6722-36	3.3	32
148	The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. *Advances in Experimental Medicine and Biology*, **2015**, 815, 349-59	3.6	30
147	Leukemia Cells Resident in Adipose Tissue Display a Pro-Inflammatory Phenotype and Induce Lipolysis and Atrophy of Adipose Tissue. *Blood*, **2015**, 126, 2765-2765	2.2	1
146	Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function. *Blood*, **2015**, 126, 842-842	2.2	
145	Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia. *Blood*, **2015**, 126, 2428-2428	2.2	
144	A Novel Isoflavone, ME-344, Targets the Cytoskeleton in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3682-3682	2.2	
143	Characterization and Targeting of Myelodysplastic Syndrome Stem Cells. *Blood*, **2015**, 126, 4104-4104	2.2	
142	IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience. *Blood*, **2015**, 126, 1443-1443	2.2	
141	Aldehyde dehydrogenases in acute myeloid leukemia. *Annals of the New York Academy of Sciences*, **2014**, 1310, 58-68	6.5	15
140	Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization. *ACS Chemical Biology*, **2014**, 9, 164-73	4.9	79
139	Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. *Haematologica*, **2014**, 99, 1277-84	6.6	83
138	Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. *Leukemia*, **2014**, 28, 1960-8	10.7	19
137	Selenium suppresses leukemia through the action of endogenous eicosanoids. *Cancer Research*, **2014**, 74, 3890-901	10.1	23

136	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. *Nature*, **2014**, 511, 90-3	50.4	129
135	Protein kinase C-associated kinase regulates NF-Β activation through inducing IKK activation. *International Journal of Oncology*, **2014**, 45, 1707-14	4.4	14
134	Metabolic effects of acute thiamine depletion are reversed by rapamycin in breast and leukemia cells. *PLoS ONE*, **2014**, 9, e85702	3.7	13
133	Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. *Molecular Cancer Therapeutics*, **2014**, 13, 1979-90	6.1	45
132	Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. *Journal of Clinical Investigation*, **2014**, 124, 222-36	15.9	52
131	Aldehyde Dehydrogenases Play a Role in Acute Myeloid Leukemia and Have Prognostic and Therapeutic Significance. *Blood*, **2014**, 124, 2238-2238	2.2	0
130	Targeting Meningeoma-1 Driven AML through Epigenetic Modulation of the Cell of Origin. *Blood*, **2014**, 124, 838-838	2.2	
129	Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. *Oncogene*, **2013**, 32, 3809-18	9.2	6
128	A phase I study of decitabine and rapamycin in relapsed/refractory AML. *Leukemia Research*, **2013**, 37, 1622-7	2.7	21
127	A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. *Leukemia Research*, **2013**, 37, 1502-8	2.7	16
126	Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. *Experimental Hematology*, **2013**, 41, 799-807.e4	3.1	31
125	BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. *Cell Stem Cell*, **2013**, 12, 329-41	18	740
124	In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. *Cancer Cell*, **2013**, 24, 45-58	24.3	118
123	Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. *Journal of Biological Chemistry*, **2013**, 288, 33542-33558	5.4	128
122	Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. *Frontiers in Pharmacology*, **2013**, 4, 9	5.6	4
121	ALDH Genes and Reactive Aldehydes Play Important Roles in HSCs and Leukemia and May Be Exploited to Treat AML. *Blood*, **2013**, 122, 2893-2893	2.2	
120	Evolution Of Acute Myelogenous Leukemia Stem Cell Properties Following Treatment and Progression. *Blood*, **2013**, 122, 883-883	2.2	1
119	Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. *Blood*, **2012**, 119, 540-50	2.2	148

118	How close are we to targeting the leukemia stem cell?. *Best Practice and Research in Clinical Haematology*, **2012**, 25, 415-8	4.2	14
117	Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. *Cell Stem Cell*, **2012**, 11, 359-72	18	50
116	Noncanonical NF-Β signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions. *Stem Cells*, **2012**, 30, 709-18	5.8	52
115	Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells. *Blood*, **2012**, 120, 206-206	2.2	2
114	Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia. *Blood*, **2012**, 120, 3549-3549	2.2	
113	Rocaglamide Selectively Eradicates Human Leukemia Stem Cells and Synergizes with Multiple Agents to Target AML Cells. *Blood*, **2012**, 120, 1338-1338	2.2	
112	Leukemia stemness signatures step toward the clinic. *Cell Stem Cell*, **2011**, 9, 185-6	18	10
111	Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. *PLoS ONE*, **2011**, 6, e23108	3.7	92
110	Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4879-83	2.9	7
109	Leukemia stem cells and microenvironment: biology and therapeutic targeting. *Journal of Clinical Oncology*, **2011**, 29, 591-9	2.2	308
108	Melampomagnolide B: a new antileukemic sesquiterpene. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 1515-9	3.4	37
107	Leukemia stem cells in 2010: current understanding and future directions. *Blood Reviews*, **2011**, 25, 75-81	11.1	55
106	Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. *Cancer Investigation*, **2011**, 29, 439-50	2.1	7
105	Targeting Redox Homeostasis As a Means to Selectively Eradicate Primary Human Leukemia Cells,. *Blood*, **2011**, 118, 3506-3506	2.2	
104	Molecular Mechanisms of Parthenolide-Mediated Pro-Apoptotic Activity in Acute Myeloid Leukemia Cells. *Blood*, **2011**, 118, 2463-2463	2.2	
103	Troglitazone and Prochloroperazine Repositioned As An Anti-Leukemia Stem Cell Drug Combination Using Chemical Genomics-Based Prediction. *Blood*, **2011**, 118, 1885-1885	2.2	0
102	Oncogene Cooperativity Analysis Reveals a Novel Set of Genes That Regulate the In Vivo Growth and Survival of Leukemia Stem Cells. *Blood*, **2011**, 118, 553-553	2.2	
101	High Throughput Screening Reveals Unique Sensitivity of CD34+CD38- AML Cells to Isotretinoin and Tretinoin. *Blood*, **2011**, 118, 1430-1430	2.2	

100	Reactive Oxygen Species (ROS) Levels Define Functional Heterogeneity in Human Leukemia Stem Cells and Represent a Critical Parameter for Therapeutic Targeting. *Blood*, **2011**, 118, 639-639	2.2	0
99	In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling. *Blood*, **2011**, 118, 758-758	2.2	
98	The NF (Nuclear factor)-B inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. *British Journal of Haematology*, **2010**, 151, 70-83	4.5	55
97	Regulation of myeloid leukaemia by the cell-fate determinant Musashi. *Nature*, **2010**, 466, 765-8	50.4	262
96	Targeting myeloid leukemia stem cells. *Science Translational Medicine*, **2010**, 2, 31ps21	17.5	18
95	NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. *Biology of Blood and Marrow Transplantation*, **2010**,	4.7	28
94	Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. *Blood*, **2010**, 116, 5983-90	2.2	66
93	A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors. *Prostate*, **2010**, 70, 1379-87	4.2	4
92	Intrinsic Requirement of MicroRNA In Hox-Based Leukemia Initiating Cell Maintenance. *Blood*, **2010**, 116, 4192-4192	2.2	1
91	Isolation and Functional Characterization of a Novel Oxidative State lowLeukemic Population with Stem Cell Properties and Potential Resistance to Chemotherapy In Acute Myeloid Leukemia.. *Blood*, **2010**, 116, 1580-1580	2.2	
90	Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104. *Blood*, **2010**, 116, 868-868	2.2	
89	Microenvironmental Changes In An In Vivo Model of Myeloid Leukemia Negatively Regulate Osteoblastic Cells.. *Blood*, **2010**, 116, 1219-1219	2.2	
88	Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. *PLoS ONE*, **2009**, 4, e8115	3.7	50
87	Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology. *Cancer Cell*, **2009**, 15, 252-4	24.3	8
86	Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. *Leukemia*, **2009**, 23, 1587-97	10.7	18
85	Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4346-9	2.9	149
84	Cancer stem cells: controversial or just misunderstood?. *Cell Stem Cell*, **2009**, 4, 203-5	18	132
83	The increasing complexity of the cancer stem cell paradigm. *Science*, **2009**, 324, 1670-3	33.3	562

82	In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. *Blood*, **2009**, 114, 4054-63	2.2	63
81	Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML).. *Blood*, **2009**, 114, 2070-2070	2.2	1
80	Analysis of the Anti-Leukemia Mechanism of Parthenolide.. *Blood*, **2009**, 114, 2734-2734	2.2	1
79	Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide.. *Blood*, **2009**, 114, 388-388	2.2	1
78	Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma.. *Blood*, **2009**, 114, 3774-3774	2.2	0
77	Rational Combinations Including a Novel Syk Inhibitor, Fostamatinib Disodium (FosD) in Diffuse Large B Cell Lymphoma.. *Blood*, **2009**, 114, 283-283	2.2	1
76	Clonally Related B-NHL Populations and Cell Lines Harbor Subsets with Significant Phenotypic and Functional Heterogeneity.. *Blood*, **2009**, 114, 1699-1699	2.2	
75	Chemical Derivatives of the Anti-Leukemia Stem Cell Compound 4-Benzyl-2-Methyl-1,2,4-Thiadiazolidine-3,5-Dione (TDZD-8) with Improved Activity.. *Blood*, **2009**, 114, 3764-3764	2.2	0
74	Synergistically Regulated Genes and Pathways in Leukemias Induced by Co-Expression of BCR-ABL and Nup98-HoxA9.. *Blood*, **2009**, 114, 3473-3473	2.2	
73	Heterogeneity in Phenotype, Functional Capacity, and Drug Sensitivity for Pediatric Acute Leukemia.. *Blood*, **2009**, 114, 2654-2654	2.2	
72	Epigenetic Signaling Is Required for HoxA9-Based Leukemic Transformation.. *Blood*, **2009**, 114, 3966-3966	2.2	
71	Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression. *Cell Research*, **2008**, 18, 281-9	24.7	26
70	Can we finally target the leukemic stem cells?. *Best Practice and Research in Clinical Haematology*, **2008**, 21, 615-20	4.2	10
69	High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 622-30	4.7	5
68	The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. *Clinical Cancer Research*, **2008**, 14, 8102-11	12.9	42
67	Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. *Annals of Oncology*, **2008**, 19, 1759-64	10.3	31
66	Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells. *Blood*, **2008**, 111, 1644-53	2.2	29
65	The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. *Blood*, **2008**, 111, 4681-9	2.2	128

64	Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. *Blood*, **2008**, 111, 5654-62	2.2	157
63	The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. *Blood*, **2008**, 112, 4184-92	2.2	18
62	Reciprocal Synergistic Interactions of Leukemic Cells with Osteoclast Progenitors in the Bone Microenvironment. *Blood*, **2008**, 112, 322-322	2.2	1
61	A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML). *Blood*, **2008**, 112, 2953-2953	2.2	
60	Inhibition of Human Lymphoma Cell Growth by the PKC-Beta Selective Inhibitor Enzastaurin (LY317615) in Combination with Multiple Therapeutic Agents.. *Blood*, **2008**, 112, 1595-1595	2.2	
59	CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML. *Blood*, **2008**, 112, 4003-4003	2.2	
58	Genes Dysregulated in a Murine Model of Leukemogenesis Comprise a Signature for Identification of Therapeutics in Humans.. *Blood*, **2008**, 112, 3349-3349	2.2	
57	The leukemic stem cell. *Best Practice and Research in Clinical Haematology*, **2007**, 20, 13-8	4.2	82
56	Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 600-6	9.4	101
55	Leukemia stem cells in a genetically defined murine model of blast-crisis CML. *Blood*, **2007**, 110, 2578-85	2.2	117
54	Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). *Blood*, **2007**, 110, 4436-44	2.2	94
53	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. *Blood*, **2007**, 110, 4427-35	2.2	319
52	Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL).. *Blood*, **2007**, 110, 2325-2325	2.2	1
51	A Search of Public Gene Expression Microarray Data Identifies Novel Agents That Selectively Eradicate AML Stem Cells.. *Blood*, **2007**, 110, 776-776	2.2	0
50	In Vivo Treatment with Prostaglandin E2 (PGE2) Selectively Expands Short-Term Hematopoietic Stem Cells.. *Blood*, **2007**, 110, 1254-1254	2.2	
49	Searching for leukemia stem cells--not yet the end of the road?. *Cancer Cell*, **2006**, 10, 253-4	24.3	26
48	A new type of stochastic dependence revealed in gene expression data. *Statistical Applications in Genetics and Molecular Biology*, **2006**, 5, Article7	1.2	29
47	Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. *Bone*, **2006**, 39, 485-93	4.7	88

46	Cancer stem cells. *New England Journal of Medicine*, **2006**, 355, 1253-61	59.2	1256
45	A Novel Orally Available Parthenolide Analog Selectively Eradicates AML Stem and Progenitor Cells.. *Blood*, **2006**, 108, 237-237	2.2	3
44	Molecular Signature for Parthenolide-Induced Apoptosis in AML CD34+ Cells Reveals Targets for Improving Induction of Leukemia-Specific Cell Death.. *Blood*, **2006**, 108, 2592-2592	2.2	1
43	Prostaglandin E2 (PGE2) Regulates Osteoblastic Jagged1 and Expands Primitive Hematopoietic Cells In Vivo.. *Blood*, **2006**, 108, 89-89	2.2	1
42	Pre-B Cell Acute Lymphoblastic Leukemia Cells Carrying a Bcr/Abl Translocation Retain Sensitivity to Minor Histocompatibility Antigen Specific T Cells but Are Resistant to Natural Killer Cells: Implications for Manipulation of Graft Versus Leukemia Effects.. *Blood*, **2006**, 108, 3247-3247	2.2	
41	In Vivo Analyses of Leukemia Stem Cells in Genetically Defined Murine Models of Chronic and Blast Crisis CML.. *Blood*, **2006**, 108, 236-236	2.2	
40	Rapid Loss of Membrane Integrity and Irreversible Commitment to Cell Death of Primary AML Stem Cells: A Novel Activity for 4-benzyl, 2-methyl,1,2,4-Thiadiazolidine,3,5 Dione (TDZD-8).. *Blood*, **2006**, 108, 2535-2535	2.2	
39	The potential of targeting malignant stem cells as a treatment for leukemia. *Future Oncology*, **2005**, 1, 205-7	3.6	2
38	The gold standard improves: a better assay for HSCs. *Blood*, **2005**, 106, 1141-1142	2.2	1
37	The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood*, **2005**, 105, 4163-9	2.2	544
36	Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. *Molecular and Cellular Biology*, **2005**, 25, 1100-12	4.8	72
35	The PKC□Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells.. *Blood*, **2005**, 106, 1483-1483	2.2	9
34	Modeling the Origins of Lymphoid Blast Crisis Via Expression of BCR/ABL in Hematopoietic Cells Mutated at the INK4a/ARF Locus.. *Blood*, **2005**, 106, 464-464	2.2	
33	Mechanisms Controlling Selective Death of Leukemia Stem Cells in Response to Parthenolide.. *Blood*, **2005**, 106, 467-467	2.2	0
32	The molecular basis of leukemia. *Hematology American Society of Hematology Education Program*, **2004**, 2004, 80-97	3.1	180
31	Mechanisms controlling pathogenesis and survival of leukemic stem cells. *Oncogene*, **2004**, 23, 7178-87	9.2	105
30	Cancer stem cell biology: from leukemia to solid tumors. *Current Opinion in Cell Biology*, **2004**, 16, 708-12	9	96
29	The hematopoietic stem cell in myelodysplasia. *Stem Cells*, **2004**, 22, 590-9	5.8	31

28	Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. *International Journal of Cancer*, **2004**, 109, 507-15	7.5	163
27	Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. *Blood*, **2004**, 104, 687-95	2.2	116
26	Considerations for targeting malignant stem cells in leukemia. *Cancer Control*, **2004**, 11, 97-104	2.2	68
25	Selective Induction of Apoptosis in Acute Myelogenous Leukemia Stem Cells by the Novel Agent Parthenolide.. *Blood*, **2004**, 104, 2542-2542	2.2	2
24	Characterization and Functional Analysis of a Murine Model for Chronic Myeloid Leukemia Stem Cells.. *Blood*, **2004**, 104, 4476-4476	2.2	
23	Osteoblastic Cells and the Hematopoietic Microenvironment: The Notch ligand Jagged1 Is Increased in Osteoblastic Stromal Cells by Parathyroid Hormone (PTH)Treatment.. *Blood*, **2004**, 104, 1284-1284	2.2	
22	Human Cytomegalovirus Infection of Primitive Hematopoietic Progenitor Cells: A Model for Latency.. *Blood*, **2004**, 104, 1703-1703	2.2	1
21	Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. *Molecular and Cellular Biology*, **2003**, 23, 8992-9002	4.8	157
20	Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. *Experimental Hematology*, **2002**, 30, 1162-9	3.1	49
19	Preferential induction of apoptosis for primary human leukemic stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 16220-5	11.5	368
18	Unique molecular and cellular features of acute myelogenous leukemia stem cells. *Leukemia*, **2002**, 16, 559-62	10.7	97
17	Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 16255-60	11.5	210
16	Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. *Blood*, **2001**, 97, 2177-9	2.2	47
15	Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. *Blood*, **2001**, 98, 2301-7	2.2	631
14	The use of adenoviral vectors for genetic manipulation and analysis of primitive hematopoietic cells. *Current Gene Therapy*, **2001**, 1, 257-65	4.3	2
13	The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. *Leukemia*, **2000**, 14, 1777-84	10.7	620
12	Clinical infection control in gene therapy: a multidisciplinary conference. *Infection Control and Hospital Epidemiology*, **2000**, 21, 659-73	2	3
11	Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes. *Human Gene Therapy*, **1999**, 10, 1875-84	4.8	16

10	Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 2988-93	11.5	364
9	Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer. *Leukemia*, **1999**, 13, 1608-16	10.7	26
8	Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. *Gene Therapy*, **1998**, 5, 465-72	4	37
7	Recent progress in identifying genes regulating hematopoietic stem cell function and fate. *Current Opinion in Cell Biology*, **1998**, 10, 716-20	9	20
6	The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 11097-102	11.5	219
5	A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 9026-30	11.5	433
4	A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. *Cell*, **1991**, 65, 1143-52	56.2	478
3	Clonal and systemic analysis of long-term hematopoiesis in the mouse. *Genes and Development*, **1990**, 4, 220-32	12.6	411
2	Cellular and developmental properties of fetal hematopoietic stem cells. *Cell*, **1990**, 61, 953-63	56.2	249
1	Targeting acute myelogenous leukemia stem cells93-108		